| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques.
|
Diabetes
|
2012
|
1.91
|
|
2
|
Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism.
|
Cell Metab
|
2008
|
1.45
|
|
3
|
Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia.
|
Endocrinology
|
2007
|
1.25
|
|
4
|
Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile.
|
Endocrinology
|
2007
|
1.23
|
|
5
|
Adropin deficiency is associated with increased adiposity and insulin resistance.
|
Obesity (Silver Spring)
|
2012
|
1.19
|
|
6
|
Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice.
|
Peptides
|
2009
|
1.16
|
|
7
|
Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency.
|
Endocrinology
|
2010
|
1.04
|
|
8
|
Novel analogs of ghrelin: physiological and clinical implications.
|
Eur J Endocrinol
|
2004
|
1.01
|
|
9
|
Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats.
|
Am J Physiol Endocrinol Metab
|
2008
|
1.01
|
|
10
|
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient.
|
J Clin Endocrinol Metab
|
2007
|
0.97
|
|
11
|
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells.
|
Am J Physiol Endocrinol Metab
|
2005
|
0.95
|
|
12
|
Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model.
|
J Cachexia Sarcopenia Muscle
|
2012
|
0.95
|
|
13
|
Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity.
|
Physiol Behav
|
2011
|
0.94
|
|
14
|
Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.
|
Kidney Int
|
2010
|
0.93
|
|
15
|
No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure.
|
Int J Cardiol
|
2008
|
0.92
|
|
16
|
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
|
J Clin Endocrinol Metab
|
2010
|
0.92
|
|
17
|
Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia?
|
Nat Clin Pract Endocrinol Metab
|
2006
|
0.91
|
|
18
|
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
|
J Clin Endocrinol Metab
|
2003
|
0.90
|
|
19
|
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules.
|
Endocrinology
|
2007
|
0.89
|
|
20
|
A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain.
|
Neuroendocrinology
|
2005
|
0.89
|
|
21
|
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives.
|
J Clin Endocrinol Metab
|
2006
|
0.89
|
|
22
|
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study.
|
Endocr Relat Cancer
|
2008
|
0.87
|
|
23
|
Constitutive somatostatin receptor activity determines tonic pituitary cell response.
|
Mol Endocrinol
|
2009
|
0.86
|
|
24
|
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid.
|
J Clin Endocrinol Metab
|
2005
|
0.86
|
|
25
|
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors.
|
ChemMedChem
|
2010
|
0.86
|
|
26
|
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion.
|
J Clin Endocrinol Metab
|
2003
|
0.86
|
|
27
|
Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2.
|
Endocrinology
|
2008
|
0.85
|
|
28
|
Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model.
|
PLoS One
|
2011
|
0.85
|
|
29
|
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
|
Mol Endocrinol
|
2007
|
0.85
|
|
30
|
Novel chimeric somatostatin analogs: facts and perspectives.
|
Eur J Endocrinol
|
2007
|
0.84
|
|
31
|
Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.
|
J Biol Chem
|
2005
|
0.83
|
|
32
|
Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
|
Biochem Biophys Res Commun
|
2002
|
0.83
|
|
33
|
Cortistatin inhibits migration and proliferation of human vascular smooth muscle cells and decreases neointimal formation on carotid artery ligation.
|
Circ Res
|
2013
|
0.83
|
|
34
|
Role of complex cyclin d1/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro.
|
Endocrinology
|
2006
|
0.82
|
|
35
|
Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas.
|
J Clin Endocrinol Metab
|
2006
|
0.82
|
|
36
|
Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand.
|
J Clin Endocrinol Metab
|
2003
|
0.81
|
|
37
|
Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
|
Clin Endocrinol (Oxf)
|
2012
|
0.80
|
|
38
|
Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
|
Neuroendocrinology
|
2006
|
0.80
|
|
39
|
Effect of application route of the ghrelin analog BIM-28131 (RM-131) on body weight and body composition in a rat heart failure model.
|
Int J Cardiol
|
2013
|
0.80
|
|
40
|
Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
|
Eur J Endocrinol
|
2008
|
0.80
|
|
41
|
Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.
|
Am J Physiol Endocrinol Metab
|
2009
|
0.80
|
|
42
|
Somatostatin analogs and chimeric somatostatin-dopamine molecules differentially regulate human growth hormone and prolactin gene expression and secretion in vitro.
|
Mol Cell Endocrinol
|
2012
|
0.79
|
|
43
|
Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.
|
Eur J Endocrinol
|
2007
|
0.79
|
|
44
|
Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
|
Mol Cell Endocrinol
|
2008
|
0.79
|
|
45
|
Adamantyl ethanone pyridyl derivatives: potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1.
|
ChemMedChem
|
2011
|
0.78
|
|
46
|
Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
|
Med Oncol
|
2004
|
0.78
|
|
47
|
Discovery of adamantyl heterocyclic ketones as potent 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
|
ChemMedChem
|
2011
|
0.77
|
|
48
|
Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
|
J Clin Endocrinol Metab
|
2004
|
0.77
|
|
49
|
Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125.
|
Pituitary
|
2007
|
0.77
|
|
50
|
Somatostatin and dopamine receptor expression in lung carcinoma cells and effects of chimeric somatostatin-dopamine molecules on cell proliferation.
|
Am J Physiol Endocrinol Metab
|
2005
|
0.77
|
|
51
|
Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
|
J Clin Endocrinol Metab
|
2003
|
0.76
|
|
52
|
Adamantyl carboxamides and acetamides as potent human 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
|
Bioorg Med Chem
|
2012
|
0.75
|
|
53
|
Novel melanocortin-4 receptor agonists that decrease food intake and body weight.
|
Adv Exp Med Biol
|
2009
|
0.75
|
|
54
|
Regulation of prostate cancer cell proliferation by somatostatin receptor activation.
|
Mol Cell Endocrinol
|
2009
|
0.75
|
|
55
|
The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat.
|
Regul Pept
|
2005
|
0.75
|
|
56
|
Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.
|
Endocr Relat Cancer
|
2009
|
0.75
|
|
57
|
The toxicology of chemokine inhibition.
|
Mini Rev Med Chem
|
2005
|
0.75
|
|
58
|
GHS-1a agonists that effectively stimulate food intake and body weight gain.
|
Adv Exp Med Biol
|
2009
|
0.75
|